JP2004537260A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537260A5 JP2004537260A5 JP2002548129A JP2002548129A JP2004537260A5 JP 2004537260 A5 JP2004537260 A5 JP 2004537260A5 JP 2002548129 A JP2002548129 A JP 2002548129A JP 2002548129 A JP2002548129 A JP 2002548129A JP 2004537260 A5 JP2004537260 A5 JP 2004537260A5
- Authority
- JP
- Japan
- Prior art keywords
- zinc finger
- use according
- amino acids
- finger protein
- consecutive amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims 33
- 101710185494 Zinc finger protein Proteins 0.000 claims 19
- 102100023597 Zinc finger protein 816 Human genes 0.000 claims 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 13
- 239000011701 zinc Substances 0.000 claims 13
- 229910052725 zinc Inorganic materials 0.000 claims 13
- 150000001413 amino acids Chemical class 0.000 claims 11
- 230000001105 regulatory effect Effects 0.000 claims 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 7
- 230000033115 angiogenesis Effects 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 241001465754 Metazoa Species 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 206010052428 Wound Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000007998 vessel formation Effects 0.000 claims 2
- 108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 101800001065 Protein 2B Proteins 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 230000006884 regulation of angiogenesis Effects 0.000 claims 1
- 230000001177 retroviral effect Effects 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Images
Claims (35)
- 血管新生を調節するための方法であって、該方法は、VEGF遺伝子内に標的部位を含むゲノムを有するヒトでない動物にジンクフィンガータンパク質を導入する工程を包含し、これによって、該ジンクフィンガータンパク質が該標的部位に結合し、そしてそれによって、該ヒトでない動物での血管新生を調節する、方法。
- 血管新生を調節するための医薬の製造における、VEGF遺伝子内の標的部位に結合するジンクフィンガータンパク質、または該VEGF遺伝子内の標的部位をコードする核酸の、使用。
- 前記ジンクフィンガータンパク質が、調節ドメインを含む融合タンパク質である、請求項1または2に記載の方法または使用。
- 前記融合タンパク質が、複数個の調節ドメインを含む、請求項3に記載の方法または使用。
- 前記調節ドメインが、活性化ドメインである、請求項3に記載の方法または使用。
- 前記活性化ドメインが、(a)VP16、(b)p65、ならびに(c)(a)および(b)の機能的フラグメントからなる群より選択される、請求項5に記載の方法または使用。
- 前記調節ドメインが、抑制ドメインである、請求項3に記載の方法または使用。
- 前記抑制ドメインが、(a)KRAB、(b)メチル結合性ドメインタンパク質 2B、(c)v−ErbA 抑制ドメイン、ならびに(d)(a)、(b)および(c)の機能的フラグメントからなる群より選択される、請求項7に記載の方法または使用。
- 前記VEGF遺伝子の複数個のスプライス改変体の発現が調節される、請求項1または2に記載の方法または使用。
- 前記導入する工程が、ジンクフィンガータンパク質をコードする核酸の導入を包含し、これによって、前記核酸が動物での前記ジンクフィンガータンパク質を生成するように発現される、請求項1に記載の方法。
- 前記ジンクフィンガータンパク質をコードする核酸が、医薬の製造において使用される、請求項2に記載の使用。
- 前記核酸が裸の形態である、請求項1または2に記載の方法または使用。
- 前記核酸が、発現ベクター内に含まれ、そしてプロモーターに作動可能に連結し、そして投与する工程が、該ベクターを前記細胞内に送達する工程を包含する、請求項1または2に記載の方法または使用。
- 前記発現ベクターが、ウイルス発現ベクターである、請求項13に記載の方法または使用。
- 前記発現ベクターが、レトロウイルス発現ベクター、アデノウイルス発現ベクター、およびAAV発現ベクターからなる群より選択される、請求項14に記載の方法または使用。
- 前記プロモーターが、誘導性プロモーターである、請求項15に記載の方法または使用。
- 前記調節ドメインが、活性化ドメインを含み、そして前記標的部位への前記ジンクフィンガータンパク質の結合が、前記VEGF遺伝子の転写を活性化する、請求項3に記載の方法または使用。
- 前記動物が、創傷を有し、そして投与される前記量が該創傷を処置するに効果的である、請求項1に記載の方法。
- 前記血管新生の調節が、創傷治癒を促進する、請求項2に記載の使用。
- 前記血管新生の調節が、腫瘍を処置する、請求項1または2に記載の方法または使用。
- 前記標的部位が、VOP32Eによって認識されるヌクレオチド配列である、請求項1または2に記載の方法または使用。
- 前記ジンクフィンガータンパク質が、VOP32Eである、請求項1または2に記載の方法または使用。
- 前記ジンクフィンガータンパク質が、新規血管形成の阻害により、血管新生を調節する、請求項1または2に記載の方法または使用。
- 前記ジンクフィンガータンパク質が、新規血管形成の刺激により、血管新生を調節する、請求項1または2に記載の方法または使用。
- 前記血管が、高透過性でない、請求項24に記載の方法または使用。
- 前記ジンクフィンガータンパク質は、6つのジンクフィンガーを含み、ここで、該6つのジンクフィンガーのそれぞれにおける位置−1〜+6が、以下の表:
- 前記標的部位が、複数個のVEGF遺伝子中に存在し、これによって、前記ジンクフィンガータンパク質は、該複数個の遺伝子中の該標的部位に結合し、この結合によって該複数個のVEGF遺伝子の発現を調節する、請求項1または2に記載の方法または使用。
- 前記導入する工程が、前記動物内に複数個のジンクフィンガータンパク質を導入する工程を包含し、それぞれのジンクフィンガータンパク質が同じ遺伝子中の異なる標的部位に結合する、請求項1または2に記載の方法または使用。
- 前記ジンクフィンガータンパク質のそれぞれが、調節ドメインを含む融合タンパク質である、請求項30に記載の方法または使用。
- それぞれのジンクフィンガータンパク質が、異なる調節ドメインと融合している、請求項31に記載の方法または使用。
- 前記血管新生の調節が、虚血を処置する、請求項1または2に記載の方法または使用。
- 前記虚血は、冠状動脈疾患に関連する、請求項33に記載の方法または使用。
- 前記前記虚血は、末梢血管疾患に関連する、請求項33に記載の方法または使用。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73360400A | 2000-12-07 | 2000-12-07 | |
US73608300A | 2000-12-12 | 2000-12-12 | |
US09/846,033 US7067317B2 (en) | 2000-12-07 | 2001-04-30 | Regulation of angiogenesis with zinc finger proteins |
PCT/US2001/046861 WO2002046412A2 (en) | 2000-12-07 | 2001-12-06 | Regulation of angiogenesis with zinc finger proteins |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007321556A Division JP4931246B2 (ja) | 2000-12-07 | 2007-12-13 | ジンクフィンガータンパク質による血管新生の調節 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004537260A JP2004537260A (ja) | 2004-12-16 |
JP2004537260A5 true JP2004537260A5 (ja) | 2006-01-19 |
Family
ID=27419178
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002548129A Withdrawn JP2004537260A (ja) | 2000-12-07 | 2001-12-06 | ジンクフィンガータンパク質による血管新生の調節 |
Country Status (6)
Country | Link |
---|---|
US (4) | US7026462B2 (ja) |
EP (1) | EP1341914A2 (ja) |
JP (1) | JP2004537260A (ja) |
AU (2) | AU2002228841C1 (ja) |
CA (1) | CA2431308C (ja) |
WO (1) | WO2002046412A2 (ja) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030104526A1 (en) | 1999-03-24 | 2003-06-05 | Qiang Liu | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
AUPQ439299A0 (en) * | 1999-12-01 | 1999-12-23 | Silverbrook Research Pty Ltd | Interface system |
US20020061512A1 (en) * | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
EP1341914A2 (en) * | 2000-12-07 | 2003-09-10 | Sangamo Biosciences Inc. | Regulation of angiogenesis with zinc finger proteins |
AU2002365796A1 (en) * | 2001-12-07 | 2003-06-17 | Toolgen, Inc. | Phenotypic screen of chimeric proteins |
US20050032186A1 (en) * | 2002-12-09 | 2005-02-10 | Kim Jin-Soo | Regulatory zinc finger proteins |
WO2005011808A1 (en) * | 2003-07-28 | 2005-02-10 | Medtronic, Inc. | Myocardial stimulation |
US20050220821A1 (en) * | 2004-03-31 | 2005-10-06 | Allergan, Inc. | Pressure sore treatment |
JP4903689B2 (ja) * | 2004-04-08 | 2012-03-28 | サンガモ バイオサイエンシズ インコーポレイテッド | 神経障害および神経変性症状を治療するための方法と組成物 |
ES2527528T3 (es) * | 2004-04-08 | 2015-01-26 | Sangamo Biosciences, Inc. | Métodos y composiciones para modular la contractilidad cardiaca |
US20060184198A1 (en) * | 2005-01-31 | 2006-08-17 | Kms Biopsy, Llc | End effector for surgical instrument, surgical instrument, and method for forming the end effector |
CA2599004C (en) | 2005-02-28 | 2015-05-26 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
WO2007106603A2 (en) * | 2006-01-06 | 2007-09-20 | The Scripps Research Institute | Specific labeling of proteins with zinc finger tags and use of zinc-finger-tagged proteins for analysis |
KR100756055B1 (ko) * | 2006-01-27 | 2007-09-07 | 연세대학교 산학협력단 | 신생혈관 생성을 조절하는 재조합 아데노바이러스 |
CA2641198A1 (en) * | 2006-02-09 | 2007-08-16 | Sangamo Biosciences, Inc. | Method for treating peripheral arterial disease with zinc finger proteins |
GB0607063D0 (en) * | 2006-04-07 | 2006-05-17 | Cellcentric Ltd | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
TWI496579B (zh) * | 2011-07-12 | 2015-08-21 | Univ Nat Cheng Kung | 類鋅手指胜肽、其表現質體、及包含其之醫藥組成物之用途 |
CA2862309A1 (en) | 2012-01-27 | 2013-08-01 | Sanbio, Inc. | Methods and compositions for modulating angiogenesis and vasculogenesis |
WO2014039585A2 (en) | 2012-09-04 | 2014-03-13 | The Scripps Research Institute | Chimeric polypeptides having targeted binding specificity |
RU2690352C2 (ru) | 2013-02-20 | 2019-05-31 | Регенерон Фармасютикалс, Инк. | Генетическая модификация крыс |
SI2986729T1 (sl) | 2013-04-16 | 2019-02-28 | Regeneron Pharmaceuticals, Inc. | Ciljana sprememba genoma podgane |
SI3080279T1 (sl) | 2013-12-11 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Postopki in sestavki za ciljano spremembo genoma |
MX2016007654A (es) | 2013-12-11 | 2017-08-15 | Regeneron Pharma | Metodos y composiciones para la modificacion dirigida de un genoma. |
CN106795521B (zh) | 2014-06-06 | 2021-06-04 | 瑞泽恩制药公司 | 用于修饰所靶向基因座的方法和组合物 |
EP3354732B1 (en) | 2014-06-23 | 2020-01-08 | Regeneron Pharmaceuticals, Inc. | Nuclease-mediated dna assembly |
AU2015279642B2 (en) | 2014-06-26 | 2021-03-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modifications and methods of use |
WO2016061374A1 (en) | 2014-10-15 | 2016-04-21 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for generating or maintaining pluripotent cells |
EP3232774B1 (en) | 2014-12-19 | 2019-10-09 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for targeted genetic modification through single-step multiple targeting |
EP3332014A4 (en) | 2015-08-07 | 2019-01-23 | Commonwealth Scientific and Industrial Research Organisation | METHOD FOR PRODUCING ANIMAL WITH GENETIC GLAND CARBON MODIFICATION |
AU2016361454A1 (en) | 2015-11-24 | 2018-06-21 | Commonwealth Scientific And Industrial Research Organisation | Production of viruses in avian eggs |
AU2016361455A1 (en) | 2015-11-24 | 2018-06-21 | Commonwealth Scientific And Industrial Research Organisation | Production of viruses in cell culture |
BR112019001783A2 (pt) | 2016-07-29 | 2019-05-07 | Regeneron Pharmaceuticals, Inc. | mamífero não humano, e, métodos para produzir o mamífero não humano e de triagem de um composto. |
IL266862B2 (en) | 2016-12-01 | 2024-01-01 | Sangamo Therapeutics Inc | Tau modulators and methods and preparations for their administration |
KR20190111067A (ko) | 2017-01-23 | 2019-10-01 | 리제너론 파마슈티칼스 인코포레이티드 | 하이드록시스테로이드 17-베타 탈수소효소 13 (hsd17b13) 변이체 및 이의 용도 |
WO2018195129A1 (en) | 2017-04-17 | 2018-10-25 | University Of Maryland, College Park | Embryonic cell cultures and methods of using the same |
US20200370058A1 (en) | 2017-06-06 | 2020-11-26 | Zymergen Inc. | A htp genomic engineering platform for improving escherichia coli |
WO2019043082A1 (en) | 2017-08-29 | 2019-03-07 | Kws Saat Se | BLUE ALEURONE ENHANCED AND OTHER SEGREGATION SYSTEMS |
NZ761329A (en) | 2017-09-29 | 2023-04-28 | Regeneron Pharma | Non-human animals comprising a humanized ttr locus and methods of use |
WO2019179445A1 (en) | 2018-03-20 | 2019-09-26 | Tsinghua University | Alzheimer's disease animal model and use thereof |
IL301193A (en) | 2018-12-20 | 2023-05-01 | Regeneron Pharma | Nuclease-mediated repeat expansion |
BR112021019512A2 (pt) | 2019-04-03 | 2022-02-15 | Regeneron Pharma | Métodos para inserir uma sequência de codificação de proteína de ligação ao antígeno e para tratar ou efetuar a profilaxia de uma doença em um animal, animal, célula, genoma, ácido nucleico doador exógeno, gene de porto seguro, e, agente de nuclease ou um ou mais ácidos nucleicos |
IL286917B (en) | 2019-04-04 | 2022-09-01 | Regeneron Pharma | Methods for scar-free insertion of targeted modifications into targeted vectors |
ES2966625T3 (es) | 2019-04-04 | 2024-04-23 | Regeneron Pharma | Roedores que comprenden un locus del factor de coagulación 12 humanizado |
AU2020286382A1 (en) | 2019-06-04 | 2021-11-04 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized TTR locus with a beta-slip mutation and methods of use |
EP3796776A1 (en) | 2019-06-07 | 2021-03-31 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized albumin locus |
US11845957B2 (en) | 2019-06-14 | 2023-12-19 | Regeneron Pharmaceuticals, Inc. | Models of tauopathy |
BR112022008861A2 (pt) | 2019-11-08 | 2022-08-23 | Regeneron Pharma | Construto de ácido nucleico, vetor, nanopartícula lipídica, célula, composição para uso na expressão de retinosquisina, método para integrar uma sequência de codificação, e, método para modificar um gene rs1 |
WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
AU2021232598A1 (en) | 2020-03-04 | 2022-09-08 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for sensitization of tumor cells to immune therapy |
WO2023055893A1 (en) * | 2021-09-30 | 2023-04-06 | Peter Biotherapeutics, Inc. | Gene regulation |
AU2022424002A1 (en) | 2021-12-29 | 2024-06-13 | Bristol-Myers Squibb Company | Generation of landing pad cell lines |
WO2023220603A1 (en) | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024031053A1 (en) | 2022-08-05 | 2024-02-08 | Regeneron Pharmaceuticals, Inc. | Aggregation-resistant variants of tdp-43 |
US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
Family Cites Families (96)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4456550A (en) | 1982-11-22 | 1984-06-26 | President And Fellows Of Harvard College | Vascular permeability factor |
DE3410650A1 (de) * | 1984-03-23 | 1985-10-03 | Kernforschungsanlage Jülich GmbH, 5170 Jülich | Mit mikroorganismen bewachsene poroese anorganische traeger, verfahren zur immobilisierung von mikroorganismen und dafuer geeignete traegerkoerper |
US5455170A (en) * | 1986-08-22 | 1995-10-03 | Hoffmann-La Roche Inc. | Mutated thermostable nucleic acid polymerase enzyme from Thermus species Z05 |
US5073492A (en) * | 1987-01-09 | 1991-12-17 | The Johns Hopkins University | Synergistic composition for endothelial cell growth |
US5317090A (en) * | 1987-12-16 | 1994-05-31 | Institut Pasteur | Steroid/thyroid hormone receptor-related gene, which is inappropriately expressed in human hepatocellular carcinoma, and which is a retinoic acid receptor |
US5324819A (en) * | 1988-04-08 | 1994-06-28 | Stryker Corporation | Osteogenic proteins |
US5340739A (en) * | 1988-07-13 | 1994-08-23 | Brigham & Women's Hospital | Hematopoietic cell specific transcriptional regulatory elements of serglycin and uses thereof |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5240848A (en) * | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
WO1990007517A1 (en) * | 1988-12-23 | 1990-07-12 | The Salk Institute For Biological Studies | Receptor transcription-repression activity compositions and methods |
US5096815A (en) * | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) * | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
US4990607A (en) * | 1989-03-14 | 1991-02-05 | The Rockefeller University | Alteration of gene expression in plants |
AU655912B2 (en) * | 1989-03-17 | 1995-01-19 | Salk Institute For Biological Studies, The | Hormone response element compositions and assay |
JP3549202B2 (ja) | 1989-03-24 | 2004-08-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 内皮細胞成長因子、その分離および発現 |
US5332671A (en) * | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
US5219739A (en) * | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
JP3393867B2 (ja) * | 1989-11-13 | 2003-04-07 | マサチユーセツツ・インステイテユート・オブ・テクノロジー | ウィルムス腫瘍遺伝子の位置決定と特徴付け |
US5578482A (en) * | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
US5219596A (en) * | 1990-08-24 | 1993-06-15 | Cargill, Incorporated | Composition and method thereof for increasing milk production in dairy cattle |
CA2051796A1 (en) | 1990-09-21 | 1992-03-22 | Marvin L. Bayne | Vascular endothelial cell growth factor ii |
JPH06503642A (ja) * | 1990-09-21 | 1994-04-21 | ザ ソーク インスティテュート フォア バイオロジカル スタディーズ | プロトオンコタンパク質c−JUNとホルモン受容体との間の機能的拮抗作用 |
US5348864A (en) * | 1991-01-25 | 1994-09-20 | E. R. Squibb & Sons, Inc. | Mouse vav proto-oncogene DNA and protein sequences |
EP0506477B1 (en) * | 1991-03-28 | 1999-06-23 | Merck & Co. Inc. | Vascular endothelial cell growth factor C subunit |
US5871907A (en) * | 1991-05-15 | 1999-02-16 | Medical Research Council | Methods for producing members of specific binding pairs |
US5324818A (en) * | 1991-08-21 | 1994-06-28 | The Regents Of The University Of Michigan | Proteins useful in the regulation of κB-containing genes |
US5243041A (en) * | 1991-08-22 | 1993-09-07 | Fernandez Pol Jose A | DNA vector with isolated CDNA gene encoding metallopanstimulin |
US5302519A (en) * | 1991-09-09 | 1994-04-12 | Fred Hutchinson Cancer Research Center | Method of producing a Mad polypeptide |
US5270170A (en) * | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
US5356802A (en) * | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5487994A (en) * | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5916794A (en) * | 1992-04-03 | 1999-06-29 | Johns Hopkins University | Methods for inactivating target DNA and for detecting conformational change in a nucleic acid |
US5436150A (en) * | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5792640A (en) * | 1992-04-03 | 1998-08-11 | The Johns Hopkins University | General method to clone hybrid restriction endonucleases using lig gene |
US5324638A (en) * | 1992-05-13 | 1994-06-28 | Sloan-Kettering Institute For Cancer Research | Brain transcription factor, nucleic acids encoding same and uses thereof |
US5776755A (en) * | 1992-10-09 | 1998-07-07 | Helsinki University Licensing, Ltd. | FLT4, a receptor tyrosine kinase |
EP0710283A4 (en) * | 1993-07-22 | 1997-07-02 | Merck & Co Inc | THE EXPRESSION OF HUMAN INTERLEUKIN-1-g (b) IN A TRANSGENIC ANIMAL |
US6140466A (en) * | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
CA2181548C (en) | 1994-01-18 | 2009-11-03 | Carlos F. Barbas, Iii | Zinc finger protein derivatives and methods therefor |
US6040157A (en) * | 1994-03-08 | 2000-03-21 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
US6608182B1 (en) | 1994-03-08 | 2003-08-19 | Human Genome Sciences, Inc. | Human vascular endothelial growth factor 2 |
ES2249762T3 (es) | 1994-03-08 | 2006-04-01 | Human Genome Sciences, Inc. | Factor de crecimiento del endotelio vascular 2. |
US5932540A (en) * | 1994-03-08 | 1999-08-03 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
WO1996006110A1 (en) | 1994-08-18 | 1996-02-29 | Gilman, Michael, Z. | Composite dna-binding proteins and materials and methods relating thereto |
ATE407205T1 (de) * | 1994-08-20 | 2008-09-15 | Gendaq Ltd | Verbesserung in bezug auf bindungsproteine bei der erkennung von dna |
DE4435919C1 (de) | 1994-10-07 | 1995-12-07 | Deutsches Krebsforsch | Zinkfinger-DNA, -Protein und ihre Verwendung |
US5814464A (en) | 1994-10-07 | 1998-09-29 | Regeneron Pharma | Nucleic acids encoding TIE-2 ligand-2 |
US6130071A (en) * | 1997-02-05 | 2000-10-10 | Helsinki University Licensing, Ltd. | Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof |
WO1998033917A1 (en) | 1994-11-14 | 1998-08-06 | The Ludwig Institute For Cancer Research | Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof |
US6645933B1 (en) | 1995-08-01 | 2003-11-11 | Helsinki University Licensing Ltd. Oy | Receptor ligand VEGF-C |
US5871902A (en) * | 1994-12-09 | 1999-02-16 | The Gene Pool, Inc. | Sequence-specific detection of nucleic acid hybrids using a DNA-binding molecule or assembly capable of discriminating perfect hybrids from non-perfect hybrids |
US5702914A (en) * | 1994-12-21 | 1997-12-30 | The Salk Institute For Biological Studies | Use of reporter genes for retinoid receptor screening assays having novel retinoid-associated response elements |
AU719001B2 (en) | 1994-12-29 | 2000-05-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
US5789538A (en) * | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5607918A (en) * | 1995-03-01 | 1997-03-04 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-B and DNA coding therefor |
US5928939A (en) | 1995-03-01 | 1999-07-27 | Ludwig Institute For Cancer Research | Vascular endothelial growth factor-b and dna coding therefor |
HU223438B1 (hu) | 1995-03-02 | 2004-07-28 | Amrad Operations Pty. Ltd. | Új növekedési faktor és ezt kódoló génszekvencia |
AU5445296A (en) | 1995-04-12 | 1996-10-30 | Cheng Cheng | Methods for preparing dna-binding proteins |
DK0848755T4 (da) | 1995-09-08 | 2011-05-23 | Genentech Inc | VEGF relateret protein |
AU1116297A (en) | 1995-11-08 | 1997-05-29 | Immunex Corporation | Flk-1 binding protein |
JP2000504220A (ja) | 1996-01-23 | 2000-04-11 | ライガル ファーマシューティカルズ インコーポレイテッド | トランス支配性細胞内作用因子ペプチドおよびrna分子のスクリーニング方法 |
WO1998002543A1 (fr) | 1996-07-15 | 1998-01-22 | Chugai Research Institute For Molecular Medicine, Inc. | Nouveaux facteurs analogues au vegf |
EP0956339B1 (en) | 1996-08-23 | 2005-10-12 | Ludwig Institute For Cancer Research | Recombinant vascular endothelial cell growth factor d (vegf-d) |
FR2752734B1 (fr) * | 1996-09-02 | 1998-11-06 | Cird Galderma | Utilisation de retinoides pour la preparation d'un medicament destine a traiter les affections liees a une surexpression de vegf |
WO1998010078A2 (en) | 1996-09-05 | 1998-03-12 | Karaplis Andrew C | CLONING OF FULL-LENGTH HUMAN PEX cDNA |
US6013780A (en) | 1996-09-06 | 2000-01-11 | Technion Research & Development Co. Ltd. | VEGF145 expression vectors |
US5939538A (en) * | 1996-10-25 | 1999-08-17 | Immusol Incorporated | Methods and compositions for inhibiting HIV infection of cells by cleaving HIV co-receptor RNA |
WO1998024811A2 (en) | 1996-12-06 | 1998-06-11 | Zymogenetics, Inc. | Vascular endothelial growth factor |
NZ514872A (en) | 1997-04-25 | 2005-01-28 | Collateral Therapeutics | Truncated VEGF-B, VRF-2, VEGF-C, PlGF, VEGF-3, poxvirus ORF-1 and poxvirus ORF-2 proteins |
DE19718249A1 (de) | 1997-04-30 | 1998-11-05 | Basf Ag | Myc-bindende Zinkfinger-Proteine, ihre Herstellung und ihre Verwendung |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6007408A (en) * | 1997-08-21 | 1999-12-28 | Micron Technology, Inc. | Method and apparatus for endpointing mechanical and chemical-mechanical polishing of substrates |
CN1345247A (zh) | 1997-12-24 | 2002-04-17 | 路德维格癌症研究所 | 表达血管内皮生长因子d的表达载体和细胞系以及治疗黑素瘤的方法 |
EP1045915A2 (en) | 1998-01-15 | 2000-10-25 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
US5972615A (en) * | 1998-01-21 | 1999-10-26 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
AU2562199A (en) | 1998-01-27 | 1999-08-09 | Eli Lilly And Company | Vegf related gene and protein |
CA2319664A1 (en) | 1998-02-06 | 1999-08-12 | Andrew Baird | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf |
US6803194B1 (en) | 1998-02-13 | 2004-10-12 | Hk Pharmaceuticals, Inc. | Use of ribozymes for functionating genes |
AU758728B2 (en) * | 1998-02-20 | 2003-03-27 | Genome Dynamics, Inc. | Method for designing DNA-binding proteins of the zinc-finger class |
EP1060261B1 (en) | 1998-03-02 | 2010-05-05 | Massachusetts Institute of Technology | Poly zinc finger proteins with improved linkers |
AU3072099A (en) | 1998-03-13 | 1999-09-27 | Human Genome Sciences, Inc. | Vascular endothelial growth factor 2 |
DK2016951T3 (da) | 1998-03-17 | 2012-09-24 | Genentech Inc | VEGF- og BMP1-homologe polypeptider |
JP2002506640A (ja) | 1998-03-17 | 2002-03-05 | ジェンダック・リミテッド | 核酸結合タンパク質 |
US6140081A (en) * | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6453242B1 (en) * | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6599692B1 (en) * | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6534261B1 (en) * | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6410519B1 (en) * | 1999-03-04 | 2002-06-25 | United States Surgical Corporation | Scar reduction |
US6610489B2 (en) * | 2000-04-28 | 2003-08-26 | Sangamo Biosciences, Inc. | Pharmacogenomics and identification of drug targets by reconstruction of signal transduction pathways based on sequences of accessible regions |
AU2001257331A1 (en) * | 2000-04-28 | 2001-11-12 | Sangamo Biosciences, Inc. | Methods for designing exogenous regulatory molecules |
CA2407745C (en) * | 2000-04-28 | 2011-11-22 | Sangamo Biosciences, Inc. | Databases of regulatory sequences; methods of making and using same |
CA2407460C (en) * | 2000-04-28 | 2013-06-25 | Sangamo Biosciences, Inc. | Targeted modification of chromatin structure |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
EP1341914A2 (en) * | 2000-12-07 | 2003-09-10 | Sangamo Biosciences Inc. | Regulation of angiogenesis with zinc finger proteins |
-
2001
- 2001-12-06 EP EP01989961A patent/EP1341914A2/en not_active Withdrawn
- 2001-12-06 AU AU2002228841A patent/AU2002228841C1/en not_active Ceased
- 2001-12-06 CA CA2431308A patent/CA2431308C/en not_active Expired - Fee Related
- 2001-12-06 US US10/006,069 patent/US7026462B2/en not_active Expired - Fee Related
- 2001-12-06 JP JP2002548129A patent/JP2004537260A/ja not_active Withdrawn
- 2001-12-06 WO PCT/US2001/046861 patent/WO2002046412A2/en active Application Filing
- 2001-12-06 AU AU2884102A patent/AU2884102A/xx active Pending
-
2005
- 2005-04-26 US US11/115,922 patent/US7605140B2/en not_active Expired - Fee Related
-
2006
- 2006-07-14 US US11/486,994 patent/US7560440B2/en not_active Expired - Fee Related
-
2009
- 2009-09-03 US US12/553,826 patent/US8071564B2/en not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004537260A5 (ja) | ||
JP7248760B2 (ja) | 肝特異的核酸調節要素ならびにその方法および用途 | |
CA2431308A1 (en) | Regulation of angiogenesis with zinc finger proteins | |
Waltenberger | Modulation of growth factor action: implications for the treatment of cardiovascular diseases | |
Witsch et al. | Roles for growth factors in cancer progression | |
Marcu et al. | Myc function and regulation | |
Barry et al. | RETRACTED: Enhanced IL-17 signalling following myocardial ischaemia/reperfusion injury | |
JP2017537611A5 (ja) | ||
US20230051499A1 (en) | Endothelium-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof | |
RU2017126975A (ru) | Модифицированные посттранскрипционные регуляторные элементы вирусов гепатита | |
ATE294863T1 (de) | Neuartige vegf-ähnliche faktoren | |
JP2000514421A (ja) | 脂肪細胞におけるアデノウイルスを介した遺伝子導入および関連のインプラント | |
Fouty et al. | p27Kip1 is important in modulating pulmonary artery smooth muscle cell proliferation | |
JP2013501816A5 (ja) | ||
Akbari et al. | A novel promoter-tethering element regulates enhancer-driven gene expression at the bithorax complex in the Drosophila embryo | |
Kitajima et al. | Human T-cell leukemia virus type I tax transformation is associated with increased uptake of oligodeoxynucleotides in vitro and in vivo. | |
JP2003503355A5 (ja) | ||
JP2005536231A (ja) | アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型rnaトランススプライシングの使用 | |
ATE312935T1 (de) | Regulatorische sequenzen für die in-vivo- expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen. | |
Bodor et al. | Modulation of Tax and PKA-mediated expression of HTLV-I promoter via cAMP response element binding and modulator proteins CREB and CREM | |
Takahashi et al. | The 5′-flanking region of the human smooth muscle cell calponin gene contains a cis-acting domain for interaction with a methylated DNA-binding transcription repressor | |
CN107073078B (zh) | 利用肝细胞生长因子和基质细胞衍生因子1α的用于预防或治疗外周动脉疾病的组合物 | |
JP2005531302A5 (ja) | ||
Ehsan et al. | Antisense and gene therapy to prevent restenosis | |
Mushimiyimana | Endothelial-targeted gene regulation for angiogenic therapy |